- Home
- MIRA vs BDRX Comparison
MIRA vs BDRX Comparison
Compare MIRA & BDRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MIRA | BDRX |
|---|---|---|
| Founded | 2020 | 2000 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.0M | 1.8M |
| IPO Year | 2023 | 2015 |
Fundamental Metrics
Financial Performance| Metric | MIRA | BDRX |
|---|---|---|
| Price | $1.11 | $0.94 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 165.0K | ★ 5.2M |
| Earning Date | 05-13-2026 | 09-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.83 | $0.60 |
| 52 Week High | $2.45 | $11.88 |
Technical Indicators
Market Signals| Indicator | MIRA | BDRX |
|---|---|---|
| Relative Strength Index (RSI) | 48.68 | 50.50 |
| Support Level | $0.90 | $0.79 |
| Resistance Level | $1.31 | $1.31 |
| Average True Range (ATR) | 0.10 | 0.09 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 65.63 | 38.63 |
Price Performance
Historical ComparisonAbout MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
About BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.